09:16 AM EDT, 08/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Wednesday that early findings from a phase I trial using its CD19 CAR-NK natural killer cell therapy showed complete responses in the first patients treated so far with late-stage Waldenstrom macroglobulinemia, a type of non-Hodgkins lymphoma.

The study is a first-in-human trial assessing the safety and preliminary efficacy of chemotherapy-free cell therapy and in combination with rituximab, the company said.

ImmunityBio ( IBRX ) shares were up over 5% in recent premarket activity.